Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Condition(s):Ovarian Cancer; Peritoneal Cancer; Fallopian Tube CancerLast Updated:August 21, 2012Withdrawn
Hide Studies Not Open or Pending
Condition(s):Ovarian Cancer; Peritoneal Cancer; Fallopian Tube CancerLast Updated:August 21, 2012Withdrawn
Condition(s):LymphomaLast Updated:September 25, 2019Withdrawn
Condition(s):NeoplasmsLast Updated:February 8, 2022Completed
Condition(s):Metastatic Cancer; Unspecified Adult Solid TumorLast Updated:September 26, 2022Completed
Condition(s):Ovarian Cancer; Drug Related Neoplasm/CancerLast Updated:March 12, 2024Recruiting
Condition(s):HRD Cancer; SCLC; Advanced Solid TumorsLast Updated:March 27, 2024Recruiting
Condition(s):Ovarian CancerLast Updated:July 26, 2022Not yet recruiting
Condition(s):Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous AdenocarcinomaLast Updated:September 26, 2023Withdrawn
Condition(s):Advanced Ovarian Cancer; Primary Peritoneal Cancer; Advanced Breast Cancer; Advanced Solid TumorsLast Updated:February 23, 2021Completed
Condition(s):Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian CancerLast Updated:March 26, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.